Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits in the top decile of US sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count).
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: 55 sponsored US clinical trials, 1 recruiting.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sponsors 55 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 46 completed. 16 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is LET, with 1 trials.
Top-decile sponsor footprint
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ranks in the top decile of sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
46 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
55 total, page 1 of 2
Study of Cannabidiol in Sanfilippo Syndrome
NCT06333041
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
NCT05753215
Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men
NCT04175678
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
NCT04037605
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
NCT03153319
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
NCT04918719
Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
NCT06342609
Long COVID-19 Rehabilitation & Recovery Research Program
NCT05398692
Prevention of Obesity in Infants of Overweight and Obese Women
NCT04782063
Diet-induced Elevations in LDL-C and Progression of Atherosclerosis
NCT05733325
Semaglutide Treatment On Coronary Progression
NCT03985384
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
NCT03637400
Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings
NCT03711292
Effect of CEAG on Inflammation and Endothelial Function
NCT03906825
Effect of Inorganic Nitrate Supplement on Blood Pressure
NCT03909789
Time Limited Trials to Reduce Non-Beneficial Intensive Care Unit Treatments
NCT04181294
Comparison of Two Application Techniques for LET Gel
NCT04203225
Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain
NCT02920528
Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
NCT02926027
The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
NCT02845752
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
NCT03009045
TTNS vs PTNS in a County Hospital System.
NCT07353944
Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need
NCT03136601
Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus
NCT03931434
ACTIMMUNE in Intermediate Osteopetrosis
NCT02666768
Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization
NCT02589067
MyoVista Measurements in Patients With Atherosclerosis and CAD
NCT02873052
Safety of Nitroglycerin for Field Treatment of STEMI
NCT02407002
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
NCT02437253
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
NCT02376010
Hormonal Mechanisms of Sleep Restriction
NCT02256865
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
NCT02090075
A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED
NCT02381392
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
NCT01966302
Effect of Aged Garlic Extract on Atherosclerosis
NCT01534910
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
NCT01382069
Fosrenol and Phosphorus Balance - Lanthanum Carbonate
NCT01581996
Comparison of Contrast Agents During CT Angiography
NCT01534975
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
NCT01404247
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
NCT01268553
Longitudinal Study of Bone Disease in Children with Mucopolysaccharidoses (MPS) I, II, and VI
NCT01521429
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
NCT00860847
Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures
NCT01708122
Clinical Trial of Growth Hormone in MPS I, II, and VI
NCT00748969
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
NCT00701636
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
NCT00561093
Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section
NCT00733278
Early Versus Delayed Surgery for Gallstone Pancreatitis
NCT00863642
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
NCT00419770
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
NCT00302744
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 4 |
| Phase 4 | 12 |
Therapeutic Areas
What is open in the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline
1 recruiting of 55 indexed (2% open); 46 completed (84%).
Phase mix: 16 late (III/IV) vs 19 early (I/II) (balanced across stages).
Top condition: LET (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: open-pipeline peers nationwide
Peers matched on 55 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 55 trials (± recruiting share)
- Connecticut Children's Medical Center · 55 trials · 27% recruiting
- Radicle Science · 55 trials · 7% recruiting
- Lexicon Pharmaceuticals · 56 trials · 2% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Alcon Research · 2% recruiting · 275 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Eisai · 2% recruiting · 287 trials
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
Related
What to do with this Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center page
55 registered trials is a research-attention snapshot, not an endorsement of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center or any single study.
- 1 of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- LET is the condition Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See LET trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline card: 55 registered trials from official public datasets.Report a data error.